A simple question about peanut allergies led Dr. Gideon Lack to a discovery that would change the way the world understands food allergies. What began as curiosity turned into decades of research that reshaped medical advice for millions of parents.
The inquiry that ignited a transformation
When Dr. Gideon Lack stood before an audience of allergists and pediatricians years ago, he asked what seemed like a straightforward question: how many of them had treated a child with a peanut allergy? In most countries, nearly every hand would go up. Peanut allergies had become one of the most common—and frightening—childhood conditions, affecting about two percent of children in the United States and showing similar numbers in the United Kingdom.
But when Lack posed the same question at a conference in Tel Aviv, only a handful of doctors raised their hands. Out of around two hundred professionals, barely three had treated such a case. The discrepancy baffled him. Jewish children in London, who shared similar genetic backgrounds with those in Israel, showed much higher rates of peanut allergy. What, then, explained this dramatic difference?
That puzzling moment set Lack on a journey that would span more than fifteen years and ultimately overturn one of medicine’s most deeply held beliefs about allergy prevention.
Discovering an unexpected pattern
The solution, as Lack subsequently discovered, was readily apparent. During his stay in Israel, he observed a distinctive aspect of the local dietary customs. Parents frequently offered their infants “Bamba,” a well-liked peanut-flavored puffed snack, starting from as early as four to six months old. This item contained substantial quantities of peanut protein, and Israeli youngsters consumed it consistently and with great enjoyment.
In contrast, parents in the United Kingdom were being told the exact opposite: to avoid exposing their infants to peanuts or other potential allergens until they were several years old. The logic behind this advice seemed sound at the time—if a food could trigger allergies, perhaps delaying exposure would prevent sensitization. But the strikingly low rate of peanut allergies among Israeli children suggested that this long-standing approach might be completely wrong.
Curious, Lack and his team compared the diets of around 10,000 children—half in Israel and half in London—who shared similar ancestry. The results were undeniable: peanut allergies were almost ten times more common among the British group. The only clear difference was when peanuts were introduced into the diet. Israeli babies were consuming the equivalent of ten peanuts a week by their first birthday, while British babies had virtually none.
Although the discovery was intriguing, it remained an observation. To transform a correlation into definitive proof, Lack required stringent scientific validation.
Questioning long-standing medical recommendations
At that juncture, the concept of intentionally introducing peanuts to babies appeared nearly irresponsible. Numerous medical professionals and guardians feared that such a method would trigger allergic responses instead of averting them. Funding bodies were reluctant, and significant ethical issues were prevalent. Despite this, Lack persevered.
In 2008, backed by the U.S. National Institutes of Health, his group initiated a substantial, meticulously managed investigation known as the LEAP trial (Learning Early About Peanut Allergy). This study concentrated on babies who faced an elevated risk of developing allergies due to severe eczema or pre-existing egg allergies. The infants were randomly assigned to one of two cohorts: one group was to completely abstain from peanuts, while the other was prompted to consume small quantities of peanut-derived foods consistently, starting as early as four months old.
Recruiting the 640 participants took two years, and the study followed them for five. The results, when they arrived, were astonishing. Among the children who avoided peanuts, nearly 14% developed peanut allergies by the age of five. In the group that consumed peanuts early, the number dropped to less than 2%. Even among children who had shown early signs of sensitivity, regular peanut consumption cut the risk of developing a full-blown allergy by more than two-thirds.
The data revealed an over 80% reduction in peanut allergy rates among those introduced to peanuts early—a breakthrough that fundamentally challenged existing medical guidance.
From discovery to transformation
When the LEAP study’s findings were published in 2015 in The New England Journal of Medicine, they marked a turning point in allergy research and pediatric nutrition. For years, official guidelines had recommended delaying exposure to allergenic foods. Now, the evidence was clear: early introduction, not avoidance, was the key to building tolerance.
The ramifications were immense. The American Academy of Pediatrics, which had previously recommended that parents delay peanut introduction until three years of age, altered its position. Revised recommendations released in 2017 advocated for the introduction of peanut-containing items as early as four to six months for the majority of infants.
The ramifications of this alteration were immediate and quantifiable. A 2024 investigation featured in Pediatrics revealed that the prevalence of peanut allergies in American children under three years old had decreased by over 40% since the implementation of the updated recommendations. This signifies that tens of thousands of young individuals are now spared from what was previously a chronic and potentially fatal allergic condition.
The ongoing evolution of medical understanding
For Dr. Lack, the event proved to be both a lesson in humility and a source of validation. He confessed that, similar to numerous other medical professionals, he had previously employed an avoidance tactic with his own offspring. Nevertheless, he also underscored that the circuitous, self-regulating essence of scientific inquiry is what ultimately propels advancement.
“The trajectory of medicine unfolds in a series of twists and turns,” he articulated. “Our recommendations are formulated upon the most current understanding available, and as new evidence emerges, our approach must similarly evolve.”
That guiding principle still informs his investigations. Currently, Lack is a co-leader of a novel initiative called the SEAL study, which again questions established beliefs. This particular endeavor examines the link between eczema and dietary sensitivities.
For a long time, medical professionals thought that food sensitivities caused eczema. However, current research indicates the opposite: infants who experience early onset eczema might be more prone to developing food allergies later on. The SEAL study seeks to investigate if proactive eczema treatment during the initial weeks of life—employing moisturizers and gentle topical remedies—could avert the emergence of allergies altogether.
The science behind early exposure
The core idea behind this novel investigation is termed the “dual-exposure hypothesis.” This theory suggests that the manner in which the immune system encounters food proteins dictates whether it identifies them as harmless or threatening. When an infant consumes food, exposure via the digestive tract instructs the immune system to accept it. However, exposure through compromised or inflamed skin, a common occurrence with eczema, could yield the opposite outcome, fostering sensitization and allergic responses.
Dr. David Hill, a pediatric allergist at the Children’s Hospital of Philadelphia and a colleague in this line of research, described the immune system as a gatekeeper. “When babies eat foods early, the immune system learns that these proteins are normal,” he said. “But when those same proteins reach the body through damaged skin, the immune system can mistake them for threats.”
Lack frequently illustrates the concept using a metaphor: “Should I politely tap on your front door and request entry, you’d likely extend a courteous welcome. However, if I were to smash through a window, your reaction would undoubtedly differ.”
If the SEAL investigation validates this hypothesis, it has the potential to revolutionize not only the avoidance of allergies but also global pediatric dermatological and dietary approaches.
Redefining how we think about allergies
The journey from that initial lecture in Tel Aviv to the modern understanding of food allergy prevention demonstrates how scientific discovery can rewrite long-held assumptions. What began as a regional curiosity became one of the most significant shifts in pediatric medicine in recent decades.
Dr. Lack’s work has already changed the lives of countless families. Where once parents were told to avoid peanuts out of fear, they are now encouraged to introduce them early and safely—often under pediatric supervision. The research has also inspired further studies on other allergenic foods, from eggs to tree nuts, suggesting that early introduction could help reduce the global burden of allergies more broadly.
For Lack and his colleagues, the goal has never been merely to publish findings but to create real-world change. As he often reminds his audiences, science advances not by being perfect but by being willing to admit when it’s wrong. The key, he believes, is staying open to evidence, even when it contradicts everything we thought we knew.
From the laughter of Israeli babies eating Bamba to the laboratory trials that followed, the story of peanut allergy prevention is a testament to persistence, humility, and the power of questioning assumptions. It reminds us that in science, as in life, progress rarely moves in a straight line—but every discovery brings us closer to understanding, healing, and prevention.
